← All Arbutus Biopharma CORP filings

Arbutus Biopharma CORP 8-K filings

NASDAQ
ABUS
Arbutus Biopharma CORP
8-K: Arbutus Biopharma Announces Positive Phase 2a Data for Imdusiran in Chronic Hepatitis B Treatment
Arbutus Biopharma's imdusiran, combined with interferon, shows promising results in reducing hepatitis B surface antigen levels and achieving sustained loss in some patients.
NASDAQ
ABUS
Arbutus Biopharma CORP
8-K: Arbutus Biopharma Shareholders Approve Increase in Share Issuance for Incentive Plan at Annual Meeting
Arbutus Biopharma shareholders approved an amendment to the 2016 Omnibus Share and Incentive Plan, increasing the number of shares available for issuance by 9.5 million.
NASDAQ
ABUS
Arbutus Biopharma CORP
8-K: Arbutus Biopharma Announces Imdusiran Data Presentations at EASL Congress 2024
Arbutus Biopharma will present new data on its hepatitis B treatment, imdusiran, at the European Association for the Study of the Liver (EASL) Congress in June.
NASDAQ
ABUS
Arbutus Biopharma CORP
8-K: Arbutus Biopharma Reports Q1 2024 Results, Provides Clinical and Corporate Update
Arbutus Biopharma announced its first quarter 2024 financial results, highlighted clinical trial progress, and provided updates on patent litigation and corporate strategy.
NASDAQ
ABUS
Arbutus Biopharma CORP
8-K: Arbutus Biopharma Announces Retirement of Chief Scientific Officer, Dr. Michael Sofia
Arbutus Biopharma's co-founder and Chief Scientific Officer, Dr. Michael Sofia, will retire effective December 31, 2024, after a 38-year career.
NASDAQ
ABUS
Arbutus Biopharma CORP
8-K: Arbutus Biopharma Secures Favorable Claim Construction Ruling in Moderna Patent Infringement Lawsuit
Arbutus Biopharma announced a favorable claim construction ruling in its patent infringement lawsuit against Moderna regarding the use of its LNP technology in Moderna's COVID-19 vaccine.
NASDAQ
ABUS
Arbutus Biopharma CORP
8-K: Arbutus Biopharma Reports 2023 Financial Results and Provides Clinical Update, Highlighting Progress in Hepatitis B Therapies
Arbutus Biopharma announced its fourth quarter and year-end 2023 financial results, along with updates on its clinical programs, including key data readouts expected in 2024.